References

• 1. Bray F, Laversanne M, Weiderpass E, Soerjomataram I The ever-increasing importance of cancer as a leading cause of premature death worldwide Cancer 2021;127(16):3029-30 google scholar
• 2. Siegel RL, Miller KD, Fuchs HE, Jemal A Cancer statistics, 2021 CA Cancer J Clin 2021;71(1):7-33 google scholar
• 3. Couzin-Frankel J Breakthrough of the year 2013 Cancer immunotherapy Science 2013;342(6165):1432-3 google scholar
• 4. Lavin Y, Mortha A, Rahman A, Merad M Regulation of macrophage development and function in peripheral tissues Nat Rev Immunol 2015;15(12):731-44 google scholar
• 5. Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, et al Polarization of tumor-associated neutrophil phenotype by TGF-beta: ”N1” versus ”N2” TAN Cancer Cell 2009;16(3):183-94 google scholar
• 6. Cerwenka A, Lanier LL Natural killer cell memory in infection, inflammation and cancer Nat Rev Immunol 2016;16(2):112-23 google scholar
• 7. Tran Janco JM, Lamichhane P, Karyampudi L, Knutson KL Tumor-infiltrating dendritic cells in cancer pathogenesis J Immunol 2015;194(7):2985-91 google scholar
• 8. Chen DS, Mellman I Oncology meets immunology: the cancer-immunity cycle Immunity 2013;39(1):1-10 google scholar
• 9. Vigneron N Human tumor antigens and cancer immunotherapy Biomed Res Int 2015;2015:948501 google scholar
• 10. Li D, Li X, Zhou WL, Huan, Y, Liang X, Jiang L , et al Genetically engineered T cells for cancer immunotherapy Sig Transduct Target Ther 2019;4:35 google scholar
• 11. Kohler G, Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495-7. google scholar
• 12. Shin SU, Morrison SL. Production and properties of chimeric antibody molecules. Methods Enzymol. 1989;178:459-76. google scholar
• 13. Chames P, Baty D. Bispecific antibodies for cancer therapy: the light at the end of the tunnel? MAbs. 2009;1(6):539-47. google scholar
• 14. Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies (Basel). 2020;9(3):34. google scholar
• 15. Maloney DG, Grillo-LOpez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, et al. IDEC-C2B8 (Rituximab) Anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-hodgkin’s lymphoma. Blood. 1997;90:2188-95. google scholar
• 16. Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163. google scholar
• 17. Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med. 2015;66:111-28. google scholar
• 18. Mendelsohn J. The epidermal growth factor receptor as a target for therapy with antireceptor monoclonal antibodies. Semin Cancer Biol. 1990;1:339-44. google scholar
• 19. Pinto AC, Ades F, de Azambuja E, Piccart-Gebhart M. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast. 2013;22 Suppl 2:S152-5 google scholar
• 20. Fornasier G, Francescon S, Baldo P. An update of efficacy and safety of cetuximab in metastatic colorectal cancer: a narrative review. Adv Ther. 2018;35(10):1497-509. google scholar
• 21. Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs. 2014;74(16):1891-925. google scholar
• 22. Kumar A, Watkins R, Vilgelm AE. Cell therapy with TILs: training and taming T cells to fight cancer. Front Immunol. 2021;12:690499. google scholar
• 23. Kazemi MH, Sadri M, Najafi A, Rahimi A, Baghernejadan Z, Khorramdelazad H, et al. Tumor-infiltrating lymphocytes for treatment of solid tumors: It takes two to tango? Front Immunol. 2022;13:1018962. google scholar
• 24. Lim FLWI, Ang SO. Emerging CAR landscape for cancer immunotherapy. Biochem Pharmacol. 2020;178:114051. google scholar
• 25. Wang X, Naranjo A, Brown CE, Bautista C, Wong CW, Chang WC, et al. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale. J Immunother. 2012;35(9):689-701. google scholar
• 26. Thudium Mueller K, Grupp SA, Maude SL, Levine JE, Pulsipher MA, Boyer MW, et al.Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma. Blood Adv. 2021;5(23):4980-91. google scholar
• 27. Chen Q, Lu L, Ma W. Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors. Cancers (Basel). 2022;14(23):5983. google scholar
• 28. McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259-71. google scholar
• 29. Kyi C, Postow MA. Checkpoint blocking antibodies in cancer immunotherapy. FEBS. Lett 2014;588(2):368-76. google scholar
• 30. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science 2018;359(6382):1350-5. google scholar
• 31. Lipson EJ, Drake CG. Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 2011;17:6958-62. google scholar
• 32. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30:825-30. google scholar
• 33. Chew HY, Dolcetti R, Simpson F. Scientifically based combination therapies with immuno-oncology checkpoint inhibitors. Br J Clin Pharmacol. 2020;86(9):1711-25. google scholar
• 34. Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z. PD-1/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol. 2021;12:7318. google scholar
• 35. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discovery. 2018;8(9):1069-86. google scholar
• 36. Salmaninejad A, Khoramshahi V, Azani A, Soltaninejad E, Aslani S, Zamani MR, et al..PD-1 and cancer: molecular mechanisms and polymorphisms. Immunogenetics. 2018;70(2):73-86. google scholar
• 37. Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway. Trends Mol Med. 2015;21:24-33. google scholar
• 38. De Sousa Linhares A, Battin C, Jutz S, Leitner J, Hafner C, Tobias J, et al. Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling. Sci Rep. 2019;9(1):11472. google scholar
• 39. Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655-68. google scholar
• 40. Chen S, Zhang Z, Zheng X, Tao H, Zhang S, Ma J, et al. Response efficacy of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. Front Oncol. 2021;11:562315. google scholar
• 41. Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S. Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Edu Book. 2019;39:147-64. google scholar
• 42. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-13. google scholar
• 43. Cho YA, Lee H, Kim DG, Kim H, Ha SY, Choi YL, et al. PD-L1 expression is significantly associated with tumor mutation burden and microsatellite iInstability score. Cancers (Basel). 2021;13(18):4659. google scholar
• 44. Ellis PM, Vella ET, Ung YC. Immune checkpoint inhibitors for patients with advanced non-small-cell lung cancer: a systematic review. Clin Lung Cancer. 2017;18(5):444-59. google scholar
• 45. Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. google scholar
• 46. Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563-7. google scholar
• 47. Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24(10):1550-8. google scholar
• 48. Saleh R, Elkord E. Treg-Mmediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168-79. google scholar
• 49. Huang Y, Snuderl M, Jain RK. Polarization of tumor-associated macrophages: a novel Strategy for vascular normalization and antitumor immunity. Cancer Cell. 2011;19(1):1-2. google scholar
• 50. Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014;515(7528):577-81. google scholar
• 51. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124. google scholar
• 52. Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368-79. google scholar
• 53. Matson V, Fessler J, Bao R, Chongsuwat T, Zha Y, Alegre ML, et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science. 2018;359:104-8. google scholar
• 54. Frankel AE, Deshmukh S, Reddy A, Lightcap J, Hayes M, McClellan S, et al. Cancer immune checkpoint inhibitor therapy and the gut microbiota. Integr Cancer Ther. 2019;18:1534735419846379. google scholar